No Data
No Data
The 4.9% Return This Week Takes ADMA Biologics' (NASDAQ:ADMA) Shareholders Three-year Gains to 645%
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards can be truly huge. Take, for example, the A
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
6 analysts have shared their evaluations of ADMA Biologics (NASDAQ:ADMA) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table provides a quick overv
ADMA Biologics Is Maintained at Buy by Mizuho
ADMA Biologics Is Maintained at Buy by Mizuho
ADMA Biologics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 31.71% Mizuho $12 → $14 Maintains Buy 05/10/2024 -5.92% Raymond James $8 → $10 Maintains Strong
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $14
Mizuho Securities analyst Anthony Petrone maintains $ADMA Biologics(ADMA.US)$ with a buy rating, and adjusts the target price from $12 to $14.According to TipRanks data, the analyst has a success rate